Corvus Pharmaceuticals (CRVS) Restructuring Costs (2024 - 2026)

Corvus Pharmaceuticals' Restructuring Costs history runs 3 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Restructuring Costs rose 31.5% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $3.3 million (up 7.11% YoY), while the FY2025 annual figure was $3.0 million, down 4.13% from the prior year.
• Restructuring Costs was $1.2 million for Q1 2026 at Corvus Pharmaceuticals, up from $561000.0 in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $1.2 million in Q1 2026 to a low of $551000.0 in Q2 2024.
• Historically, Restructuring Costs has averaged $813000.0 across 3 years, with a median of $780000.0 in 2024.
• Biggest YoY gain for Restructuring Costs was 53.9% in 2025; the steepest drop was 28.08% in 2025.
• A 3-year view of Restructuring Costs shows it stood at $780000.0 in 2024, then declined by 28.08% to $561000.0 in 2025, then soared by 121.75% to $1.2 million in 2026.
• The last three Restructuring Costs figures came in at $1.2 million (Q1 2026), $561000.0 (Q4 2025), and $617000.0 (Q3 2025), per Business Quant data.